




yield of hexafluoroacetone. Perfluoroisobutylene oxide requires 320° for 24 hr for significant formation of hexafluoroacetone and difluorocarbene, suggesting that the displacement of difluorocarbene from carbonyl fluoride by bis(trifluoromethyl)carbene at 180° occurs by way of excited perfluoroisobutylene oxide.


Difluorocarbene reacts with OPF_3 in two ways: as a reducing agent and as a fluorinating agent (eq 1 and 2). These reactions are isokinetic at 60° At



100°, reaction 1 accounts for 95% of the products and reaction 2 for 5%. At 25°, reaction 1 accounts for 5% and reaction 2 for 95%.⁸ From the product ratios we estimate that reaction 1 has an enthalpy and entropy of activation 18 kcal mole⁻¹ and 50 eu, respectively, greater than those of reaction 2. By analogy to the carbene-ketone adduct⁶ we suggest that addition of CF_2 to the PO bond is the first step common to reactions 1 and 2. Reaction 1 then pro-





ceeds by breaking the PO bond, or the PC bond, or both. Reaction 2 proceeds by way of a fluorine shift from C to P via a very tight bicyclic transition state to



give $\text{F}_4\text{PC}(=\text{O})\text{F}$ (not isolable at 25°) which shifts fluorine once more to give CO and PF_5 .

Bis(trifluoromethyl)carbene (from bis(trifluoromethyl)diazomethane) reacts with OPF_3 at 160° or in sunlight at 25° to give hexafluoroacetone.

We are applying the reduction of OPF_3 as a probe for carbenes in more complex systems. For example, pentafluoroethyltetrafluorophosphorane, $\text{CF}_3\text{CF}_2\text{PF}_4$, decomposes at 240° in platinum with a half-life of 12 hr to give tetrafluoroethylene and pentafluorophosphorane. Trifluoromethylfluorocarbene is revealed as an intermediate because trifluoroacetyl fluoride is obtained in 80% yield with a threefold excess of OPF_3 .



Similarly, *n*-perfluoropropyltetrafluorophosphorane decomposes at 240° predominantly via an α -fluorine shift.

and hexafluoroacetone has been demonstrated by Moore.⁷ The boiling point is 2°; infrared absorption is at 1500, 1335, 1280, 1255, 1225, 1090, 1025, 985, 725, 718, and 712 cm⁻¹. ¹⁹F nmr resonances are at 72 ppm for CF_3 and 112 ppm for CF_2 from FCCl_3 .

(7) Reported by D. P. Carlson and A. S. Milian, Fourth International Symposium on Fluorine Chemistry, Estes Park, Colo., 1967.

(8) The 25° source of CF_2 used was $(\text{CF}_3)_2\text{PF}_3 \rightarrow \text{CF}_2 + \text{CF}_3\text{PF}_4$ (half-life 3 days). $(\text{CF}_3)_2\text{PF}_3 \rightarrow 3\text{CF}_2 + \text{PF}_3$ served for the experiments at 60° (half-life 6 months) and 100° (half-life 12 hr). Experiments were run in sealed-glass or platinum tubes for at least two half-lives. The product ratios are independent of pressure. Reaction 1 was also observed using perfluorocyclopropane as CF_2 source⁹ at 220° or perfluoro(methylcyclopropane) at 190°. The latter extrudes CF_2 exclusively, with no indication of CF_3CF .

(9) B. Atkinson and D. McKeagan, *Chem. Commun.*, 189 (1966).

Walter Mahler

Contribution No. 1362, Central Research Department
Experimental Station, E. I. du Pont de Nemours and Co.
Wilmington, Delaware 19898

Received August 17, 1967

Pyrrolo[2,3-*d*]pyrimidine Nucleoside Antibiotics. Total Synthesis and Structure of Toyocamycin, Unamycin B, Vengicide, Antibiotic E-212, and Sangivamycin (BA-90912)¹

Sir:

The antibiotic toyocamycin was first isolated from *Streptomyces toyocaensis* by Nishimura and coworkers² and later by Ohkuma³ from *Streptomyces* strain 1922. Recently antibiotic 1037⁴ has been shown⁵ to be identical with toyocamycin. The unusual biological properties of toyocamycin^{2,3} and its antitumor activity^{6,7} have stimulated considerable interest in this antibiotic. Preliminary degradation studies^{3,8} resulted in a tentative structure assignment for toyocamycin as 4-amino-5-cyano-7-(β -D-ribofuranosyl)pyrrolo[2,3-*d*]pyrimidine. Sangivamycin has been isolated from an unidentified species of *Streptomyces*⁹ and was at that time referred to as BA-90912. Sangivamycin was reported to possess cytotoxicity against HeLa cells grown in cell cultures and to exhibit significant activity against Leukemia 1210 in mice. Sangivamycin has produced no evidence of toxicity in humans at maximally tolerated doses and is presently undergoing human clinical trial against leukemia.¹⁰ It has been noted¹¹ that sangivamycin is structurally similar to toyocamycin. However, a recent review¹² points to the fact that the actual site of glycosidation, anomeric configuration, and structure of the sugar moiety for sangivamycin and toyocamycin have not been unequivocally established.

We now wish to report a total synthesis of toyocamycin (VIa) and sangivamycin (VIb) and the unequivocal assignment of their structures.

Ring closure of 2-amino-5-bromo-3,4-dicyanopyrrole¹³ with formamidine acetate in 2-ethoxyethanol at reflux temperature furnished a 65% yield of 4-amino-6-bromo-5-cyanopyrrolo[2,3-*d*]pyrimidine (I): mp 300°, $\lambda_{\text{max}}^{\text{EtOH}}$ 284 (ϵ 13,800) and 250 m μ (ϵ 7800). A mixture of I, acetic anhydride, and xylene was heated at reflux temperature for 18 hr to afford the monoacetylated product, 4-acetamido-6-bromo-5-cyanopyrrolo[2,3-*d*]pyrimidine (II, 94%), mp 265° dec.

A mixture of II and 1,2,3,5-tetra-*O*-acetyl- β -D-ribofuranose was heated at 175° in the presence of a catalytic amount of bis(*p*-nitrophenyl) phosphate¹⁴ for

(1) This work was supported in part by Research Contract No. PH 43-65-1041, Cancer Chemotherapy National Service Center, National Cancer Institute, National Institutes of Health, Public Health Service.

(2) H. Nishimura, K. K. Katagiri, K. Sato, M. Mayama, and N. Shimaoka, *J. Antibiotics* (Tokyo), **9A**, 60 (1956).

(3) K. Ohkuma, *ibid.*, **13A**, 361 (1960).

(4) H. Yamamoto, S. Fujii, K. Nakazawa, A. Miyake, H. Hitomi, and M. Imanishi, *Ann. Rept. Takeda Res. Lab.*, **16**, 28 (1952).

(5) A. Aszalos, P. Lemanski, R. Robison, S. Davis, and B. Berk, *J. Antibiotics* (Tokyo), **19A**, 285 (1966).

(6) G. Acs, E. Reich, and M. Mori, *Proc. Natl. Acad. Sci. U.S.A.*, **52**, 493 (1964).

(7) M. Saneyoshi, R. Tokuzen, and F. Fukuoka, *Gann*, **56**, 219 (1965).

(8) K. Ohkuma, *J. Antibiotics* (Tokyo), **14A**, 343 (1961).

(9) K. V. Rao and R. W. Renn, *Antimicrobial Agents Chemotherapy*, **77** (1963).

(10) J. A. Cavins, *Proc. Am. Assoc. Cancer Res.*, **7**, 12 (1966); C. G. Zubrod, S. Shepartz, J. Leiter, K. M. Endicott, L. M. Carrese, and C. G. Baker, *Cancer Chemotherapy Rept.*, **50**, 496 (1966); J. A. Cavins, *et al.*, *ibid.*, **51**, 197 (1967).

(11) K. V. Rao, 150th National Meeting of the American Chemical Society, Atlantic City, N. J., Sept 1965, Abstract 24P.

(12) J. J. Fox, K. A. Watanabe, and A. Bloch, *Progr. Nucleic Acid Res. Mol. Biol.*, **5**, 271 (1966).

(13) W. J. Middleton, V. A. Englehardt, and B. S. Fisher, *J. Am. Chem. Soc.*, **80**, 2822 (1958).

(14) T. Hashizume and H. Iwamura, *Tetrahedron Letters*, 3095 (1965).


25 min. This reaction mixture was then applied to a column of Woelm neutral alumina and eluted with mixtures of petroleum ether-chloroform. Preparative layer chromatography was then utilized to furnish the acetylated nucleoside III as a pale yellow syrup. Complete deacetylation of III was accomplished with methanolic ammonia at room temperature to furnish a 92% yield of 4-amino-6-bromo-5-cyano-7-(β -D-ribofuranosyl)pyrrolo[2,3-*d*]pyrimidine (IV): mp 245–247° dec; $\lambda_{\text{max}}^{\text{EtOH}}$ 284 m μ (ϵ 18,300). Recent studies in this laboratory have shown that ribosidation or alkylation¹⁵ of 6-substituted 4-amino-5-cyanopyrrolo[2,3-*d*]pyrimidines in the pyrimidine ring produces a 15–30-m μ bathochromic shift while alkylation in the pyrrole ring produces only a small hypsochromic shift if any shift is observed at all. The ultraviolet absorption maxima recorded in ethanol for I and the nucleoside derivative IV are identical. Thus, the D-ribofuranosyl moiety was assigned to the pyrrole ring at N-7.

Removal of the 6-bromo group of IV with 5% palladium on powdered charcoal in a hydrogen atmosphere afforded an 88% yield of 4-amino-5-cyano-7-(β -D-ribofuranosyl)pyrrolo[2,3-*d*]pyrimidine (VIa, toyocamycin): mp 243°; $\lambda_{\text{max}}^{\text{EtOH}}$ 288 (shoulder) (ϵ 9800), 278 (ϵ 5100), and 231 m μ (ϵ 9300); infrared absorption band at 2230 cm⁻¹ (CN); $[\alpha]_D^{25} -55.6 \pm 1.3^\circ$ (*c* 1.0, 0.1 N HCl).¹⁶ A mixture melting point of the above product and toyocamycin¹⁷ showed no depression. The ultraviolet, infrared, and pmr spectra of VIa and toyocamycin were superimposable. The chromatographic mobilities of VIa in four solvent systems were identical with those observed for natural toyocamycin.¹⁷ The 2', 3'-*O*-isopropylidene-5'-*O*-tosyl derivative of toyocamycin was prepared by standard procedures and warm dimethyl sulfoxide-*d*₆ effected intramolecular quaternization to yield 2',3'-*O*-isopropylidene-5'-*N*₁-toyocamycin cyclonucleoside. The appearance in the pmr of a sharp singlet at δ 6.65 (1 H) was assigned to the anomeric proton which established¹⁸ the β configuration for all nucleosides here reported. Thus the site of ribosidation, anomeric configuration, and structure of the carbohydrate moiety for toyocamycin have been confirmed and the structure for toyocamycin established as 4-amino-5-cyano-7-(β -D-ribofuranosyl)pyrrolo[2,3-*d*]pyrimidine (VIa).

Unamycin B isolated from a culture of *Streptomyces fungicidicus*^{19,20} and antibiotic E-212 isolated²¹ from *Streptomyces* sp. E-212 have been described as related to toyocamycin.^{19,21} Authentic samples^{22,23} of unamycin B and antibiotic E-212 were rigorously compared with toyocamycin in our laboratory, which proved that

these antibiotics were identical with toyocamycin. Vengicide has been isolated from *Streptomyces vendargensis*^{24,25} and since a number of physical properties of this antibiotic were similar to those of toyocamycin, a sample was obtained for comparison.²⁶ Vengicide was found in our laboratory also to be identical with toyocamycin.

The total synthesis and complete structural assignment of sangivamycin (VIb) has also been achieved. Treatment of IV with 30% hydrogen peroxide in concentrated ammonium hydroxide solution at room temperature furnished a crystalline product in 65% yield, mp 221°. This nucleoside was assigned the structure 4-amino-6-bromo-5-carboxamido-7-(β -D-ribofuranosyl)pyrrolo[2,3-*d*]pyrimidine (V) on the basis of elemental analysis¹⁶ and pmr spectra. Removal of the 6-bromo group from V with 5% palladium on powdered charcoal in a hydrogen atmosphere pro-



VIa, R = -CN (toyocamycin)

b, R = -C(=O)NH₂ (sangivamycin)

c, R = -C(=O)OH
d, R = -H (tubercidin)

(15) R. L. Tolman, R. K. Robins, and L. B. Townsend, *J. Heterocyclic Chem.*, **4**, 230 (1967).

(16) Satisfactory elemental analyses were obtained for all new compounds reported. Optical rotation of an authentic sample of toyocamycin under similar conditions was $[\alpha]_D^{25} -55.7 \pm 0.9^\circ$.

(17) The authors wish to thank Dr. Haruo Nishimura, Shionogi and Co. Ltd. Osaka, and Dr. Kazuhiko Ohkuma, Institute of Physical and Chemical Research, Tokyo, for authentic samples of toyocamycin.

(18) R. J. Rousseau, R. K. Robins, and L. B. Townsend, *J. Heterocyclic Chem.*, **4**, 311 (1967).

(19) M. Matsuoka and H. Umezawa, *J. Antibiotics* (Tokyo), **13A**, 114 (1960).

(20) M. Matsuoka, *ibid.*, **13A**, 121 (1960).

(21) K. Kikuchi, *ibid.*, **8A**, 145 (1955).

(22) The authors wish to thank Dr. Hamao Umezawa, Institute for Microbial Chemistry, Tokyo, for an authentic sample of unamycin B.

(23) The authors wish to thank Dr. Mitsuo Rikimaru of the Tohoku University School of Medicine, Sendai, Japan, for an authentic sample of antibiotic E-212.

(24) A. P. Struyk and A. A. Stheeman, *Chem. Abstr.*, **51**, 10009a (1957); British Patent 764,198.

(25) A. P. Struyk and A. A. Stheeman, *Chem. Abstr.*, **62**, 11114g (1965); Netherlands Patent 109,006.

(26) The authors wish to thank Dr. J. C. Hoogerheide, Koninklijke, Nederlandsche Gist-en Spiritusfabriek, Delft, The Netherlands, for a sample of vengicide.

ceeded smoothly to afford 4-amino-5-carboxamido-7-(β -D-ribofuranosyl)pyrrolo[2,3-*d*]pyrimidine (VIb) in 83% yield: mp 260°, $\lambda_{\text{max}}^{\text{EtOH}}$ 278 (ϵ 15,100) and 229 m μ (ϵ 8200); $[\alpha]^{26\text{D}} -45.7 \pm 1.9^\circ$ (*c* 1.0, 0.1 *N* HCl).²⁷ A comparison of chromatographic mobilities, ultraviolet absorption, and infrared spectra of VIb with those of an authentic sample of sangivamycin²⁷ established that the samples were identical. Additional evidence for the structural assignment of sangivamycin and toyocamycin was furnished by the conversion of sangivamycinic acid to the related pyrrolo[2,3-*d*]pyrimidine antibiotic tubercidin since the structure of tubercidin has previously been unequivocally established.²⁸ Sangivamycinic acid (VIc) has been previously prepared⁸ as an intermediate but was never characterized. Sangivamycinic acid hydrochloride was prepared in our laboratory by heating toyocamycin at reflux temperature in 3 *N* hydrochloric acid in a nitrogen atmosphere for 12 hr to obtain a 55% yield of VIc: mp 238° dec; $\lambda_{\text{max}}^{\text{EtOH}}$ 279 (ϵ 13,500) and 231 m μ (ϵ 7600). Decarboxylation was accomplished by immersion of VIc in a preheated oil bath (238°) for approximately 10 sec; this gave a dark amber melt. An aqueous ethanol extract of this melt furnished tubercidin (VID, 4-amino-7-(β -D-ribofuranosyl)pyrrolo[2,3-*d*]pyrimidine) in 13% yield. The identity of VID was confirmed by rigorous comparison with authentic tubercidin.²⁹

(27) The authors wish to thank Dr. K. V. Rao for an authentic sample of sangivamycin hydrochloride which showed an optical rotation of $[\alpha]^{26\text{D}} -42.2 \pm 1.9^\circ$ under similar conditions.

(28) Y. Mizuno, M. Ikehara, K. A. Watanabe, S. Suzuki, and T. Itoh, *J. Org. Chem.*, **28**, 3329 (1963).

(29) The authors wish to thank Dr. Saburo Suzuki for an authentic sample of tubercidin.

(30) National Aeronautics and Space Administration Fellow, 1965–1967.

Richard L. Tolman,³⁰ Roland K. Robins
Leroy B. Townsend

Department of Chemistry, University of Utah
Salt Lake City, Utah 84112

Received September 21, 1967

The Rearrangement of N,N'-Dimethylhydrazobenzene¹

Sir:

Although the benzidine rearrangement has been the subject of many investigations,² its intimate mechanism continues to be the subject of considerable discussion and disagreement, with some³ preferring a concerted mechanism in which the new bonds found in the products are formed as the nitrogen–nitrogen bond in the hydrazoaromatic is broken, and others⁴ favoring a process in which bond scission and formation occur sequentially. Even among those holding the latter view there are differences regarding the nature of the intermediate, some^{4a} supporting a π complex and others^{4b} arguing for a solvent-caged cation–radical pair.

Most of the product and kinetic data for the benzidine

rearrangement can be equally well explained by either a concerted or a stepwise mechanism. However, *p*-semidine (*p*-aminodiphenylamine) formation is difficult to interpret in terms of the polar transition-state mechanism (the most recent proposal for the concerted process) since bond formation over a distance of about 5.3 Å would be required.⁵ Indeed, *p*-semidine-type products have seldom been isolated from benzidine rearrangements⁶ and in most cases in which they have been obtained the conditions were unusual. These facts have led to the suggestion³ that *p*-semidines are not formed in the normal benzidine rearrangement. This conclusion has been used to support the polar transition state.³ On the other hand, the formation of a *p*-semidine would be a logical outcome of the π complex or cation–radical mechanisms since the fragments resulting from nitrogen–nitrogen bond breaking would be able to assume a variety of positions with respect to each other.

A *p*-semidine-like compound has been detected among the products resulting from rearrangement of N,N'-dimethylhydrazobenzene at 25° in 25% aqueous methanol using 0.01 *M* hydrochloric acid as catalyst. Analysis was accomplished by the isotope dilution procedure. The following compounds were observed: 50.7% N,N'-dimethyl-4,4'-diaminobiphenyl (benzidine), 20.3% N,N'-dimethyl-2,4'-diaminobiphenyl (diphenylene), 0.9% N,N'-dimethyl-2,2'-diaminobiphenyl (*o*-benzidine); 15.5% N,N'-dimethyl-*o*-aminodiphenylamine (*o*-semidine); 3.0% N,N'-dimethyl-*p*-aminodiphenylamine (*p*-semidine), and 11.2% N-methylaniline (disproportionation product). The benzidine and diphenylene were isolated as the N,N'-dibenzoyl derivatives, the semidines as monobenzenamides, and the disproportionation product as the acetamide. These derivatives were purified by chromatography followed by several recrystallizations (often from two different solvents). From the material balance, it is obvious that essentially all of the products have been accounted for in this analysis.

The kinetics of acid-catalyzed rearrangement of N,N'-dimethylhydrazobenzene in 25% aqueous methanol at 25° were also investigated. The experimental results conform to an expression of the following type: rate = $k_2(\text{H}^+)(\text{substrate})$. The rates of isomerization of the 4,4'-dichloro and 4,4'-dimethyl derivatives of N,N'-dimethylhydrazobenzene were also determined, and the second-order rate constants for the three hydrazo compounds were correlated by σ^+ constants and a ρ value of –11.85.

The rearrangement of N,N'-dimethylhydrazobenzene is similar to the isomerization of hydrazobenzene in that the major products are the benzidine and the diphenylene.⁷ The ratio of these two products is about the same in both reactions, about 2.3–2.5. However, the two rearrangements differ in that sizable amounts of both the *o*- and *p*-semidine products result from the reaction involving N,N'-dimethylhydrazobenzene. The formation of a *p*-semidine is particularly interesting since it cannot arise from con-

(1) Research supported by National Science Foundation Grant GP-1970.

(2) See H. J. Shine, "Aromatic Rearrangements," Elsevier Publishing Company, New York, N. Y., 1967, pp 126–179, for an excellent review of this subject.

(3) D. V. Banthorpe, E. D. Hughes, and C. K. Ingold, *J. Chem. Soc.*, 2864 (1964).

(4) (a) M. J. S. Dewar and A. P. Marchand, *Ann. Rev. Phys. Chem.*, **16**, 338 (1965); M. J. S. Dewar in "Molecular Rearrangements," Vol. 1, P. de Mayo, Ed., Interscience Publishers, Inc., New York, N. Y., 1963; (b) G. S. Hammond and J. S. Clovis, *J. Org. Chem.*, **28**, 3283, 3290 (1963).

(5) The intermolecular distance in the very weakly bonded molecular complexes (2.5–3.5 Å) is less.

(6) M. Vecera, J. Petranek, and J. Gasparic, *Collection Czech. Chem. Commun.*, **22**, 1603 (1957); P. Jacobson, *Ann.*, **428**, 76 (1922).

(7) R. B. Carlin, R. G. Nelb, and R. C. Odioso, *J. Am. Chem. Soc.*, **73**, 1002 (1951).